LABELS · 0142c57f-6211-4638-8c48-c215686871b8
Lynparza
Open original source → · Download preserved record
Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.
- Label effective date
- 2025-07-10
- Captured
- 2026-09-09T23:37:39.774134+00:00
- Current indication reconciliation
- Not reconciled
Indications and usage: exact source text
- 1 INDICATIONS AND USAGE Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 ) 1.1 First-Line Maintenance Treatment of BRCA -mutated Advanced Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.2 First-line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.3 Maintenance Treatment of BRCA-mutated Recurrent Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.4 Adjuvant Treatment of Germline BRCA -mutated HER2-negative High Risk Early Breast Cancer Lynparza is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [ see Dosage and Administration (2.1) ]. 1.5 Germline BRCA -mutated HER2-negative Metastatic Breast Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.6 First-Line Maintenance Treatment of Germline BRCA -mutated Metastatic Pancreatic Adenocarcinoma Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.7 HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.8 Treatment of BRCA -mutated Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Prednisone or Prednisolone Lynparza is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] .
Full extracted label fields
- application numbers
- NDA208558
- boxed warning exact
- brand names
- Lynparza
- current indication status
- not_reconciled
- dailymed set url
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa
- generic names
- OLAPARIB
- id
- 0142c57f-6211-4638-8c48-c215686871b8
- indications and usage exact
- 1 INDICATIONS AND USAGE Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 ) 1.1 First-Line Maintenance Treatment of BRCA -mutated Advanced Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.2 First-line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.3 Maintenance Treatment of BRCA-mutated Recurrent Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.4 Adjuvant Treatment of Germline BRCA -mutated HER2-negative High Risk Early Breast Cancer Lynparza is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [ see Dosage and Administration (2.1) ]. 1.5 Germline BRCA -mutated HER2-negative Metastatic Breast Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.6 First-Line Maintenance Treatment of Germline BRCA -mutated Metastatic Pancreatic Adenocarcinoma Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.7 HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.8 Treatment of BRCA -mutated Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Prednisone or Prednisolone Lynparza is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] .
- indications and usage tables exact
- is original packager
- true
- manufacturer names
- AstraZeneca Pharmaceuticals LP
- matched search terms
- cancer
- package ndcs
- 0310-0668-60
- 0310-0668-12
- 0310-0668-95
- 0310-0679-60
- 0310-0679-12
- 0310-0679-95
- 0310-0569-60
- 0310-0569-12
- 0310-0578-60
- 0310-0578-12
- product ndcs
- 0310-0569
- 0310-0668
- 0310-0679
- 0310-0578
- product types
- HUMAN PRESCRIPTION DRUG
- recent major changes exact
- Warnings and Precautions ( 5.2 , 5.4 ) 7/2025
- record type
- complete_spl_indications_section_candidate
- routes
- ORAL
- rxcuis
- 1942482
- 1942485
- 1942487
- 1942489
- source batch
- file
- /private/tmp/cancer-full-research/indications/raw/labels-00000.json
- meta
- disclaimer
- Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
- last updated
- 2026-09-09
- results
- limit
- 100
- skip
- 0
- total
- 830
- sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl effective time
- 20250710
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- substance names
- OLAPARIB
- uniis
- WOH1JD9AR8
- verification flags
- oncology_keyword_candidate_not_clinically_classified
- spl_text_not_verified_identical_to_latest_approved_label
- individual_indications_not_split_or_reconciled
- fda_label_posted_after_spl_effective_date_requires_version_review
Drugs@FDA application source records
- application number
- NDA208558
- payload
- all indexed label documents
- Appl No
- 208558
- Application Docs Date
- 2017-08-17 00:00:00
- Application Docs ID
- 49443
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208558s000lbl.pdf
- Submission No
- 1
- Submission Type
- ORIG
- Appl No
- 208558
- Application Docs Date
- 2018-01-12 00:00:00
- Application Docs ID
- 51041
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf
- Submission No
- 1
- Submission Type
- SUPPL
- Appl No
- 208558
- Application Docs Date
- 2018-02-07 00:00:00
- Application Docs ID
- 52493
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s002lbl.pdf
- Submission No
- 2
- Submission Type
- SUPPL
- Appl No
- 208558
- Application Docs Date
- 2018-09-27 00:00:00
- Application Docs ID
- 55632
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s005lbl.pdf
- Submission No
- 5
- Submission Type
- SUPPL
- Appl No
- 208558
- Application Docs Date
- 2018-12-19 00:00:00
- Application Docs ID
- 56808
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s006lbl.pdf
- Submission No
- 6
- Submission Type
- SUPPL
- Appl No
- 208558
- Application Docs Date
- 2019-07-09 00:00:00
- Application Docs ID
- 59291
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208558s009lbl.pdf
- Submission No
- 9
- Submission Type
- SUPPL
- Appl No
- 208558
- Application Docs Date
- 2020-01-10 00:00:00
- Application Docs ID
- 61467
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208558Orig1s010lblrpl.pdf
- Submission No
- 10
- Submission Type
- SUPPL
- Appl No
- 208558
- Application Docs Date
- 2020-05-08 00:00:00
- Application Docs ID
- 62859
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf
- Submission No
- 13
- Submission Type
- SUPPL
- Appl No
- 208558
- Application Docs Date
- 2020-05-19 00:00:00
- Application Docs ID
- 63150
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf
- Submission No
- 14
- Submission Type
- SUPPL
- Appl No
- 208558
- Application Docs Date
- 2020-11-03 00:00:00
- Application Docs ID
- 65135
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf
- Submission No
- 18
- Submission Type
- SUPPL
- Appl No
- 208558
- Application Docs Date
- 2020-12-10 00:00:00
- Application Docs ID
- 65563
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s016lbl.pdf
- Submission No
- 16
- Submission Type
- SUPPL
- Appl No
- 208558
- Application Docs Date
- 2021-03-12 00:00:00
- Application Docs ID
- 66770
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208558s019s020lbl.pdf
- Submission No
- 20
- Submission Type
- SUPPL
- all submission records
- Appl No
- 208558
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 31
- Submission Status
- AP
- Submission Status Date
- 2025-07-10 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 208558
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 29
- Submission Status
- AP
- Submission Status Date
- 2023-09-12 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 208558
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 28
- Submission Status
- AP
- Submission Status Date
- 2023-11-06 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 208558
- Review Priority
- PRIORITY
- Submission Class Code ID
- 2
- Submission No
- 26
- Submission Status
- AP
- Submission Status Date
- 2022-08-26 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 208558
- Review Priority
- PRIORITY
- Submission Class Code ID
- 2
- Submission No
- 25
- Submission Status
- AP
- Submission Status Date
- 2023-05-31 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 208558
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 24
- Submission Status
- AP
- Submission Status Date
- 2022-10-27 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 208558
- Review Priority
- PRIORITY
- Submission Class Code ID
- 2
- Submission No
- 23
- Submission Status
- AP
- Submission Status Date
- 2022-03-11 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 208558
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 21
- Submission Status
- AP
- Submission Status Date
- 2022-01-31 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 208558
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 20
- Submission Status
- AP
- Submission Status Date
- 2021-03-11 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 208558
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 19
- Submission Status
- AP
- Submission Status Date
- 2021-03-11 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 208558
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 18
- Submission Status
- AP
- Submission Status Date
- 2020-11-02 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 208558
- Review Priority
- PRIORITY
- Submission Class Code ID
- 2
- Submission No
- 16
- Submission Status
- AP
- Submission Status Date
- 2020-12-07 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- application number
- NDA208558
- approval interpretation
- Application linkage and approved submission are not indication-level current approval verification
- current indication status
- not_reconciled
- drugsfda url
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558
- has approved submission record
- true
- latest approved submission date
- 2025-07-10
- latest label selection rule
- max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
- latest posted label documents
- Appl No
- 208558
- Application Docs Date
- 2025-07-11 00:00:00
- Application Docs ID
- 82819
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf
- Submission No
- 31
- Submission Type
- SUPPL
- official application record
- Appl No
- 208558
- Appl Public Notes
- Appl Type
- NDA
- Sponsor Name
- ASTRAZENECA
- openfda application present
- true
- products
- Active Ingredient
- OLAPARIB
- Appl No
- 208558
- Drug Name
- LYNPARZA
- Form
- TABLET;ORAL
- Product No
- 001
- Reference Drug
- 1
- Reference Standard
- 0
- Strength
- 100MG
- marketing status
- Prescription
- Active Ingredient
- OLAPARIB
- Appl No
- 208558
- Drug Name
- LYNPARZA
- Form
- TABLET;ORAL
- Product No
- 002
- Reference Drug
- 1
- Reference Standard
- 1
- Strength
- 150MG
- marketing status
- Prescription
Source passages and status connections
Passage 1 · indication intro context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- incomplete_colon_led_indication_intro
- clinical review status
- pending
- content role
- indication_intro_context
- context span
- end
- 309
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-e42eef90a24586989b98
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-d3cf44171b91b195cc19
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- end
- 93
- end exclusive
- true
- exact text
- is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 33
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 109
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 0
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 2 · positive indication candidate
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 591
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced e
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-edcb8df581f897696fd0
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-323a173c2567ee2e2833
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- end
- 93
- end exclusive
- true
- exact text
- is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 33
- qualifier mentions
- context exact
- • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somat
- kind
- age
- polarity
- not_inferred
- span
- end
- 159
- end exclusive
- true
- exact text
- adult patients
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 145
- context exact
- th deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in com
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 263
- end exclusive
- true
- exact text
- BRCA -mutated advanced epithelial ovarian
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 222
- context exact
- or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in com
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 263
- end exclusive
- true
- exact text
- advanced epithelial ovarian
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 236
- context exact
- eritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 390
- end exclusive
- true
- exact text
- first-line platinum-based chemotherapy
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 352
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 391
- end exclusive
- true
- exact text
- • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 110
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 3 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 679
- end exclusive
- true
- exact text
- leterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or pa
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 192
- current approval status
- not_reconciled
- duplicate text group
- dup-6a3cf94a09575fde86f5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-49f73c10b8cdea484a7c
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 479
- end exclusive
- true
- exact text
- Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 392
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 4 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 693
- end exclusive
- true
- exact text
- or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 280
- current approval status
- not_reconciled
- duplicate text group
- dup-4751f6ed93bf4c5d05a4
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-e1fb423041be48a44450
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 493
- end exclusive
- true
- exact text
- ( 1.1 , 2.1 )
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 480
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 5 · positive indication candidate
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 1048
- end exclusive
- true
- exact text
- itoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the m
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 294
- current approval status
- not_reconciled
- duplicate text group
- dup-784b761a66dab684d8ed
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-dfc3f362084b492c7ba1
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- end
- 93
- end exclusive
- true
- exact text
- is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 33
- qualifier mentions
- context exact
- mbination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary
- kind
- age
- polarity
- not_inferred
- span
- end
- 575
- end exclusive
- true
- exact text
- adult patients
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 561
- context exact
- izumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in com
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 608
- end exclusive
- true
- exact text
- advanced epithelial ovarian
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 581
- context exact
- eritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either:
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 848
- end exclusive
- true
- exact text
- first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either:
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 697
- context exact
- • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 675
- end exclusive
- true
- exact text
- in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete o
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 496
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 848
- end exclusive
- true
- exact text
- • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either:
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 494
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 6 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1111
- end exclusive
- true
- exact text
- ncer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or susp
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 649
- current approval status
- not_reconciled
- duplicate text group
- dup-078cb25aef5eefdc2cae
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-adbfc1056b59f32e9b91
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • a deleterious or suspected deleterious BRCA mutation, and/or
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 903
- end exclusive
- true
- exact text
- BRCA mutation
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 890
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 911
- end exclusive
- true
- exact text
- • a deleterious or suspected deleterious BRCA mutation, and/or
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 849
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 7 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1134
- end exclusive
- true
- exact text
- inum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germl
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 712
- current approval status
- not_reconciled
- duplicate text group
- dup-10fda02194c688876485
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-161db864fccda899cb3c
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 934
- end exclusive
- true
- exact text
- • genomic instability.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 912
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 8 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1222
- end exclusive
- true
- exact text
- and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peri
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 735
- current approval status
- not_reconciled
- duplicate text group
- dup-6a3cf94a09575fde86f5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-d095a22e5bfd72411b4b
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 1022
- end exclusive
- true
- exact text
- Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 935
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 9 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1236
- end exclusive
- true
- exact text
- status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer,
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 823
- current approval status
- not_reconciled
- duplicate text group
- dup-d75070475700ee8c89a1
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-dce68d1e1d15ab221c1e
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 1036
- end exclusive
- true
- exact text
- ( 1.2 , 2.1 )
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1023
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 10 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1508
- end exclusive
- true
- exact text
- by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected delete
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 837
- current approval status
- not_reconciled
- duplicate text group
- dup-083a9e8aaf6caa94ee52
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-1db4e78298d64a741c11
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somat
- kind
- age
- polarity
- not_inferred
- span
- end
- 1086
- end exclusive
- true
- exact text
- adult patients
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1072
- context exact
- th deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in co
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1190
- end exclusive
- true
- exact text
- BRCA-mutated recurrent epithelial ovarian
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1149
- context exact
- s or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in co
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1190
- end exclusive
- true
- exact text
- recurrent epithelial ovarian
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1162
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 1308
- end exclusive
- true
- exact text
- • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1037
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 11 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1596
- end exclusive
- true
- exact text
- spected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1109
- current approval status
- not_reconciled
- duplicate text group
- dup-6a3cf94a09575fde86f5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-618ce2622e3831137548
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 1396
- end exclusive
- true
- exact text
- Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1309
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 12 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1624
- end exclusive
- true
- exact text
- pian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1197
- current approval status
- not_reconciled
- duplicate text group
- dup-4b8dc22b9d1e67486fc3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-d4f8a6d3d75e938762e2
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 1424
- end exclusive
- true
- exact text
- ( 1.3 , 2.1 ) Breast cancer
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1397
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 13 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1874
- end exclusive
- true
- exact text
- eal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-neg
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1225
- current approval status
- not_reconciled
- duplicate text group
- dup-61de6783b3571c67f2b3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-9086d2e0067c003a8cd9
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human ep
- kind
- age
- polarity
- not_inferred
- span
- end
- 1471
- end exclusive
- true
- exact text
- adult patients
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1457
- context exact
- adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have b
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1560
- end exclusive
- true
- exact text
- BRCA m human epidermal growth factor recepto
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1516
- context exact
- eterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemothe
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1609
- end exclusive
- true
- exact text
- HER2)-negative high risk early breast cancer
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1565
- context exact
- • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1478
- end exclusive
- true
- exact text
- adjuvant treatment of adult patients with d
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1435
- context exact
- ve high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1673
- end exclusive
- true
- exact text
- neoadjuvant or adjuvant chemotherapy
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1637
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 1674
- end exclusive
- true
- exact text
- • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1425
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 14 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1962
- end exclusive
- true
- exact text
- h deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvan
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1475
- current approval status
- not_reconciled
- duplicate text group
- dup-6a3cf94a09575fde86f5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-a974f22dc35f48441a67
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 1762
- end exclusive
- true
- exact text
- Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1675
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 15 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1976
- end exclusive
- true
- exact text
- (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1563
- current approval status
- not_reconciled
- duplicate text group
- dup-e2fefbe165bc12f43985
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-ccd8d01d457c3528bef6
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 1776
- end exclusive
- true
- exact text
- ( 1.4 , 2.1 )
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1763
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 16 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2196
- end exclusive
- true
- exact text
- ve high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy ba
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1577
- current approval status
- not_reconciled
- duplicate text group
- dup-33a207293d7d86d5982d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-546992ff71e559537f4e
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-neg
- kind
- age
- polarity
- not_inferred
- span
- end
- 1814
- end exclusive
- true
- exact text
- adult patients
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1800
- context exact
- patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuv
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1910
- end exclusive
- true
- exact text
- HER2-negative metastatic breast cancer who h
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1866
- context exact
- n treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1995
- end exclusive
- true
- exact text
- metastatic setting
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1977
- context exact
- deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastat
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1925
- end exclusive
- true
- exact text
- metastatic breast cancer who have been treate
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1880
- context exact
- reast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1963
- end exclusive
- true
- exact text
- neoadjuvant
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1952
- context exact
- who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1995
- end exclusive
- true
- exact text
- adjuvant or metastatic setting
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1965
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 1996
- end exclusive
- true
- exact text
- • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1777
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 17 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2365
- end exclusive
- true
- exact text
- of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1797
- current approval status
- not_reconciled
- duplicate text group
- dup-df28a2f9b9fe4cc53260
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-e48d1afe6b3d5d92ee2a
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 2165
- end exclusive
- true
- exact text
- Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1997
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 18 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2453
- end exclusive
- true
- exact text
- djuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progress
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 1966
- current approval status
- not_reconciled
- duplicate text group
- dup-6a3cf94a09575fde86f5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-d75e664092ed8f4cc6d8
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 2253
- end exclusive
- true
- exact text
- Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2166
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 19 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2485
- end exclusive
- true
- exact text
- r should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a fir
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2054
- current approval status
- not_reconciled
- duplicate text group
- dup-c98dedca65ad91d7e478
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-e01c78110a579cb47b39
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 2285
- end exclusive
- true
- exact text
- ( 1.5 , 2.1 ) Pancreatic cancer
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2254
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 20 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2729
- end exclusive
- true
- exact text
- a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious g
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2086
- current approval status
- not_reconciled
- duplicate text group
- dup-fd7f24e346b2a697ce17
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-748481c993963c744a19
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastati
- kind
- age
- polarity
- not_inferred
- span
- end
- 2335
- end exclusive
- true
- exact text
- adult patients
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2321
- context exact
- patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-l
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2429
- end exclusive
- true
- exact text
- metastatic pancreatic adenocarcinoma whose
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2386
- context exact
- patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-lin
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2431
- end exclusive
- true
- exact text
- metastatic pancreatic adenocarcinoma whose di
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2386
- context exact
- whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 2528
- end exclusive
- true
- exact text
- first-line platinum-based chemotherapy regimen
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2482
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 2529
- end exclusive
- true
- exact text
- • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2286
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 21 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2817
- end exclusive
- true
- exact text
- ients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castrat
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2330
- current approval status
- not_reconciled
- duplicate text group
- dup-6a3cf94a09575fde86f5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-10db9420b0aaaee025f6
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 2617
- end exclusive
- true
- exact text
- Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2530
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 22 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2847
- end exclusive
- true
- exact text
- noma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2418
- current approval status
- not_reconciled
- duplicate text group
- dup-b96a000e6cd56345592e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-66f3b71237bc9d353d3b
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 2647
- end exclusive
- true
- exact text
- ( 1.6 , 2.1 ) Prostate cancer
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2618
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 23 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3134
- end exclusive
- true
- exact text
- gressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patie
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2448
- current approval status
- not_reconciled
- duplicate text group
- dup-3c7283e105d666acbdde
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-be320f3369b63a7ed85d
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • for the treatment of adult patients with deleterious or suspected deleterious germline or somat
- kind
- age
- polarity
- not_inferred
- span
- end
- 2685
- end exclusive
- true
- exact text
- adult patients
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2671
- context exact
- somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment w
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2842
- end exclusive
- true
- exact text
- metastatic castration-resistant prostate ca
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2799
- context exact
- somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment wit
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2844
- end exclusive
- true
- exact text
- metastatic castration-resistant prostate canc
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2799
- context exact
- stant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 2933
- end exclusive
- true
- exact text
- prior treatment with enzalutamide or abiraterone
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2885
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 2934
- end exclusive
- true
- exact text
- • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2648
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 24 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3222
- end exclusive
- true
- exact text
- e or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castrat
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2735
- current approval status
- not_reconciled
- duplicate text group
- dup-6a3cf94a09575fde86f5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-c98c030c6b94adad68d3
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 3022
- end exclusive
- true
- exact text
- Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2935
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 25 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3236
- end exclusive
- true
- exact text
- sistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2823
- current approval status
- not_reconciled
- duplicate text group
- dup-df59e73e918d6638cd56
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-2956d1cf7dff905f5186
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 3036
- end exclusive
- true
- exact text
- ( 1.7 , 2.1 )
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3023
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 26 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3460
- end exclusive
- true
- exact text
- te cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 ) 1.1 First-Line Maintenance Treatment of BRCA -mutated Advanced Ovarian Cancer Lynparza is indicat
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 2837
- current approval status
- not_reconciled
- duplicate text group
- dup-69c1b998aa0ee71690d3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-835c6e62846a836e495f
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- aterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( B
- kind
- age
- polarity
- not_inferred
- span
- end
- 3137
- end exclusive
- true
- exact text
- adult patients
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3123
- context exact
- of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC).
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3224
- end exclusive
- true
- exact text
- BRCA -mutated ( BRCA m) metastatic castratio
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3180
- context exact
- eleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3249
- end exclusive
- true
- exact text
- metastatic castration-resistant prostate canc
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3204
- context exact
- • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 3218
- end exclusive
- true
- exact text
- in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic cas
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3039
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 3260
- end exclusive
- true
- exact text
- • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC).
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3037
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 27 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3548
- end exclusive
- true
- exact text
- iraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 ) 1.1 First-Line Maintenance Treatment of BRCA -mutated Advanced Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleter
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3061
- current approval status
- not_reconciled
- duplicate text group
- dup-6a3cf94a09575fde86f5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-6a03313ffae1114ecf64
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 3348
- end exclusive
- true
- exact text
- Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3261
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 28 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3562
- end exclusive
- true
- exact text
- rious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 ) 1.1 First-Line Maintenance Treatment of BRCA -mutated Advanced Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3149
- current approval status
- not_reconciled
- duplicate text group
- dup-cd38393e5f280a9e8908
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-c120e141ad20011549fa
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 3362
- end exclusive
- true
- exact text
- ( 1.8 , 2.1 )
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3349
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 29 · positive indication candidate
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 3942
- end exclusive
- true
- exact text
- cted deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 ) 1.1 First-Line Maintenance Treatment of BRCA -mutated Advanced Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.2 First-line Maintenance Treatment of HRD-positive Advanced Ovarian C
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3163
- current approval status
- not_reconciled
- duplicate text group
- dup-786bed219dc1a9a0b8db
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-619cfd8135c6a2000b60
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- end
- 3462
- end exclusive
- true
- exact text
- is indicated
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3450
- qualifier mentions
- context exact
- ncer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somat
- kind
- age
- polarity
- not_inferred
- span
- end
- 3510
- end exclusive
- true
- exact text
- adult patients
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3496
- context exact
- 1.1 First-Line Maintenance Treatment of BRCA -mutated Advanced Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patie
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3447
- end exclusive
- true
- exact text
- BRCA -mutated Advanced Ovarian Cancer Lynpar
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3403
- context exact
- th deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in com
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3614
- end exclusive
- true
- exact text
- BRCA -mutated advanced epithelial ovarian
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3573
- context exact
- 1.1 First-Line Maintenance Treatment of BRCA -mutated Advanced Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with dele
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3460
- end exclusive
- true
- exact text
- Advanced Ovarian Cancer Lynparza is indicat
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3417
- context exact
- or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in com
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3614
- end exclusive
- true
- exact text
- advanced epithelial ovarian
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3587
- context exact
- 1.1 First-Line Maintenance Treatment of BRCA -mutated Advanced Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced e
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 3537
- end exclusive
- true
- exact text
- First-Line Maintenance Treatment of BRCA -mutated Advanced Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspec
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3367
- context exact
- eritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 3741
- end exclusive
- true
- exact text
- first-line platinum-based chemotherapy
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3703
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 3742
- end exclusive
- true
- exact text
- 1.1 First-Line Maintenance Treatment of BRCA -mutated Advanced Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3363
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 30 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4070
- end exclusive
- true
- exact text
- leterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.2 First-line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adu
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3543
- current approval status
- not_reconciled
- duplicate text group
- dup-b538941cc844d165b385
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-482a235f06776c5a34a1
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 3870
- end exclusive
- true
- exact text
- Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] .
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3743
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 31 · positive indication candidate
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 4554
- end exclusive
- true
- exact text
- complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.2 First-line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administra
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3671
- current approval status
- not_reconciled
- duplicate text group
- dup-fc1a74bb09b9597915ed
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-73d8bb47274cfd67abae
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- end
- 4001
- end exclusive
- true
- exact text
- is indicated
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3989
- qualifier mentions
- context exact
- mbination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary
- kind
- age
- polarity
- not_inferred
- span
- end
- 4081
- end exclusive
- true
- exact text
- adult patients
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4067
- context exact
- 1.2 First-line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab Lynparza is indicated in combination with bevac
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3967
- end exclusive
- true
- exact text
- Advanced Ovarian Cancer in Combination with
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3924
- context exact
- izumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in com
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4114
- end exclusive
- true
- exact text
- advanced epithelial ovarian
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4087
- context exact
- 1.2 First-line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelia
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 4045
- end exclusive
- true
- exact text
- First-line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab Lynparza is indicated in combination with bevacizumab for the mai
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3875
- context exact
- eritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either:
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 4354
- end exclusive
- true
- exact text
- first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either:
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4203
- context exact
- intenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or part
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 4127
- end exclusive
- true
- exact text
- in Combination with Bevacizumab Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian t
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3948
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 4354
- end exclusive
- true
- exact text
- 1.2 First-line Maintenance Treatment of HRD-positive Advanced Ovarian Cancer in Combination with Bevacizumab Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either:
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 3871
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 32 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4617
- end exclusive
- true
- exact text
- ncer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.3 Maintenance Treatment of BRCA-mutated Recurre
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4155
- current approval status
- not_reconciled
- duplicate text group
- dup-078cb25aef5eefdc2cae
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-89170ffebbb09629a0b1
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • a deleterious or suspected deleterious BRCA mutation, and/or
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 4409
- end exclusive
- true
- exact text
- BRCA mutation
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4396
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 4417
- end exclusive
- true
- exact text
- • a deleterious or suspected deleterious BRCA mutation, and/or
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4355
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 33 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4640
- end exclusive
- true
- exact text
- inum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.3 Maintenance Treatment of BRCA-mutated Recurrent Ovarian Cancer Lynpa
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4218
- current approval status
- not_reconciled
- duplicate text group
- dup-10fda02194c688876485
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-7f8f9cc3ba272d346d05
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 4440
- end exclusive
- true
- exact text
- • genomic instability.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4418
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 34 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4767
- end exclusive
- true
- exact text
- and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.3 Maintenance Treatment of BRCA-mutated Recurrent Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4241
- current approval status
- not_reconciled
- duplicate text group
- dup-b538941cc844d165b385
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-2013825ef22ccc6f8054
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 4567
- end exclusive
- true
- exact text
- Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ].
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4441
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 35 · positive indication candidate
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 5126
- end exclusive
- true
- exact text
- us or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.3 Maintenance Treatment of BRCA-mutated Recurrent Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.4 Adjuvant Treatment of Germline BRCA -mutated HER2-negative High Risk
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4368
- current approval status
- not_reconciled
- duplicate text group
- dup-a646b8e19ad40098afde
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-8f29c19e88c91e099248
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- end
- 4656
- end exclusive
- true
- exact text
- is indicated
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4644
- qualifier mentions
- context exact
- ncer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somat
- kind
- age
- polarity
- not_inferred
- span
- end
- 4704
- end exclusive
- true
- exact text
- adult patients
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4690
- context exact
- 1.3 Maintenance Treatment of BRCA-mutated Recurrent Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patie
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 4641
- end exclusive
- true
- exact text
- BRCA-mutated Recurrent Ovarian Cancer Lynpar
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4597
- context exact
- th deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in co
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 4808
- end exclusive
- true
- exact text
- BRCA-mutated recurrent epithelial ovarian
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4767
- context exact
- 1.3 Maintenance Treatment of BRCA-mutated Recurrent Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with dele
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4654
- end exclusive
- true
- exact text
- Recurrent Ovarian Cancer Lynparza is indicat
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4610
- context exact
- s or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in co
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4808
- end exclusive
- true
- exact text
- recurrent epithelial ovarian
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4780
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 4926
- end exclusive
- true
- exact text
- 1.3 Maintenance Treatment of BRCA-mutated Recurrent Ovarian Cancer Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4568
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 36 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5253
- end exclusive
- true
- exact text
- spected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.4 Adjuvant Treatment of Germline BRCA -mutated HER2-negative High Risk Early Breast Cancer Lynparza is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterio
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4727
- current approval status
- not_reconciled
- duplicate text group
- dup-b538941cc844d165b385
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-4ca194b321fd4bdd1126
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 5053
- end exclusive
- true
- exact text
- Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ].
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4927
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 37 · positive indication candidate
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 5615
- end exclusive
- true
- exact text
- who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.4 Adjuvant Treatment of Germline BRCA -mutated HER2-negative High Risk Early Breast Cancer Lynparza is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [ see Dosage and Administration (2.1) ]. 1.5 Germline BRCA -mutated HER2-negative Metastatic Breast Cancer Lynpa
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 4854
- current approval status
- not_reconciled
- duplicate text group
- dup-5b2fd78dd5abdb5086a3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-31f68ec5629d9225c6f2
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- end
- 5168
- end exclusive
- true
- exact text
- is indicated
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5156
- qualifier mentions
- context exact
- Cancer Lynparza is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCA m human epi
- kind
- age
- polarity
- not_inferred
- span
- end
- 5213
- end exclusive
- true
- exact text
- adult patients
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5199
- context exact
- 1.4 Adjuvant Treatment of Germline BRCA -mutated HER2-negative High Risk Early Breast Cancer Lynparza is indicated for the adjuvant treatme
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5133
- end exclusive
- true
- exact text
- BRCA -mutated HER2-negative High Risk Early
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5089
- context exact
- leterious gBRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemothe
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5350
- end exclusive
- true
- exact text
- HER2)-negative high risk early breast cancer
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5306
- context exact
- 1.4 Adjuvant Treatment of Germline BRCA -mutated HER2-negative High Risk Early Breast Cancer Lynparza is in
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5101
- end exclusive
- true
- exact text
- Adjuvant Treatment of Germline BRCA -mutate
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5058
- context exact
- High Risk Early Breast Cancer Lynparza is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCA m human epidermal
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5220
- end exclusive
- true
- exact text
- adjuvant treatment of adult patients with d
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5177
- context exact
- ve high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5414
- end exclusive
- true
- exact text
- neoadjuvant or adjuvant chemotherapy
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5378
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 5415
- end exclusive
- true
- exact text
- 1.4 Adjuvant Treatment of Germline BRCA -mutated HER2-negative High Risk Early Breast Cancer Lynparza is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5054
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 38 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5743
- end exclusive
- true
- exact text
- th deleterious or suspected deleterious gBRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [ see Dosage and Administration (2.1) ]. 1.5 Germline BRCA -mutated HER2-negative Metastatic Breast Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5216
- current approval status
- not_reconciled
- duplicate text group
- dup-b538941cc844d165b385
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-9a3af4aac6c33b8bbc71
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 5543
- end exclusive
- true
- exact text
- Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [ see Dosage and Administration (2.1) ].
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5416
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 39 · positive indication candidate
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 6051
- end exclusive
- true
- exact text
- cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [ see Dosage and Administration (2.1) ]. 1.5 Germline BRCA -mutated HER2-negative Metastatic Breast Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy ba
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5344
- current approval status
- not_reconciled
- duplicate text group
- dup-0859d879c9e8b46d2da7
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-4ee8b4f40ed85ea4f824
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- end
- 5631
- end exclusive
- true
- exact text
- is indicated
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5619
- qualifier mentions
- context exact
- ic Breast Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-neg
- kind
- age
- polarity
- not_inferred
- span
- end
- 5667
- end exclusive
- true
- exact text
- adult patients
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5653
- context exact
- 1.5 Germline BRCA -mutated HER2-negative Metastatic Breast Cancer Lynparza is indicated for the treatment of adult pa
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5601
- end exclusive
- true
- exact text
- BRCA -mutated HER2-negative Metastatic Breas
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5557
- context exact
- patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5757
- end exclusive
- true
- exact text
- HER2-negative metastatic breast cancer
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5719
- context exact
- treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5850
- end exclusive
- true
- exact text
- metastatic setting
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5832
- context exact
- 1.5 Germline BRCA -mutated HER2-negative Metastatic Breast Cancer Lynparza is indicated for the treatment of adult patients with deleterious or su
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5630
- end exclusive
- true
- exact text
- Metastatic Breast Cancer Lynparza is indicate
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5585
- context exact
- deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5757
- end exclusive
- true
- exact text
- metastatic breast cancer
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5733
- context exact
- east cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5817
- end exclusive
- true
- exact text
- neoadjuvant
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5806
- context exact
- who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5827
- end exclusive
- true
- exact text
- adjuvant
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5819
- context exact
- treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5850
- end exclusive
- true
- exact text
- metastatic setting
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5832
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 5851
- end exclusive
- true
- exact text
- 1.5 Germline BRCA -mutated HER2-negative Metastatic Breast Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5544
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 40 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 6220
- end exclusive
- true
- exact text
- adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.6 First-Line Maintenance Treatment of Germline BRCA -mutated Metastat
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5652
- current approval status
- not_reconciled
- duplicate text group
- dup-df28a2f9b9fe4cc53260
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-954fdd5b1a4391287360
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 6020
- end exclusive
- true
- exact text
- Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5852
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 41 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 6348
- end exclusive
- true
- exact text
- juvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.6 First-Line Maintenance Treatment of Germline BRCA -mutated Metastatic Pancreatic Adenocarcinoma Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5821
- current approval status
- not_reconciled
- duplicate text group
- dup-b538941cc844d165b385
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-38dbc1de8ffe35e96811
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 6148
- end exclusive
- true
- exact text
- Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] .
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6021
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 42 · positive indication candidate
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 6712
- end exclusive
- true
- exact text
- endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.6 First-Line Maintenance Treatment of Germline BRCA -mutated Metastatic Pancreatic Adenocarcinoma Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.7 HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer Ly
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 5949
- current approval status
- not_reconciled
- duplicate text group
- dup-65eb91bebfd7f7e9b09e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-58fd9bd2d11d763658c6
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- end
- 6270
- end exclusive
- true
- exact text
- is indicated
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6258
- qualifier mentions
- context exact
- noma Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastati
- kind
- age
- polarity
- not_inferred
- span
- end
- 6318
- end exclusive
- true
- exact text
- adult patients
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6304
- context exact
- 1.6 First-Line Maintenance Treatment of Germline BRCA -mutated Metastatic Pancreatic Adenocarcinoma Lynparza is indicated for the maintenance treatment o
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 6242
- end exclusive
- true
- exact text
- BRCA -mutated Metastatic Pancreatic Adenocar
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6198
- context exact
- patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-l
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 6412
- end exclusive
- true
- exact text
- metastatic pancreatic adenocarcinoma whose
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6369
- context exact
- First-Line Maintenance Treatment of Germline BRCA -mutated Metastatic Pancreatic Adenocarcinoma Lynparza is indicated for the maintenance treatment of adult patient
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6257
- end exclusive
- true
- exact text
- Metastatic Pancreatic Adenocarcinoma Lynparza
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6212
- context exact
- patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-lin
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6414
- end exclusive
- true
- exact text
- metastatic pancreatic adenocarcinoma whose di
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6369
- context exact
- 1.6 First-Line Maintenance Treatment of Germline BRCA -mutated Metastatic Pancreatic Adenocarcinoma Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pan
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 6323
- end exclusive
- true
- exact text
- First-Line Maintenance Treatment of Germline BRCA -mutated Metastatic Pancreatic Adenocarcinoma Lynparza is indicated for the maintenance treatment of adult patients with
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6153
- context exact
- whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 6511
- end exclusive
- true
- exact text
- first-line platinum-based chemotherapy regimen
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6465
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 6512
- end exclusive
- true
- exact text
- 1.6 First-Line Maintenance Treatment of Germline BRCA -mutated Metastatic Pancreatic Adenocarcinoma Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6149
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 43 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 6840
- end exclusive
- true
- exact text
- ients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.7 HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6313
- current approval status
- not_reconciled
- duplicate text group
- dup-b538941cc844d165b385
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-427b330c78dbe5646ef1
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 6640
- end exclusive
- true
- exact text
- Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] .
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6513
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 44 · positive indication candidate
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 7216
- end exclusive
- true
- exact text
- at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] . 1.7 HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.8 Treatment of BRCA -mutated Metastatic Castration-Resistant Prostate
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6441
- current approval status
- not_reconciled
- duplicate text group
- dup-72822400e5374f93e822
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-27950ef74a2bef80616d
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- end
- 6731
- end exclusive
- true
- exact text
- is indicated
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6719
- qualifier mentions
- context exact
- Prostate Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somat
- kind
- age
- polarity
- not_inferred
- span
- end
- 6767
- end exclusive
- true
- exact text
- adult patients
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6753
- context exact
- 1.7 HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer Lynparza is indicated for the treatment of adult patien
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 6705
- end exclusive
- true
- exact text
- Metastatic Castration-Resistant Prostate Ca
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6662
- context exact
- somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment w
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 6924
- end exclusive
- true
- exact text
- metastatic castration-resistant prostate ca
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6881
- context exact
- 1.7 HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer Lynparza is indicated for the treatment of adult patients
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6707
- end exclusive
- true
- exact text
- Metastatic Castration-Resistant Prostate Canc
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6662
- context exact
- somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment wit
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6926
- end exclusive
- true
- exact text
- metastatic castration-resistant prostate canc
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6881
- context exact
- stant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 7015
- end exclusive
- true
- exact text
- prior treatment with enzalutamide or abiraterone
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6967
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 7016
- end exclusive
- true
- exact text
- 1.7 HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6641
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 45 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 7343
- end exclusive
- true
- exact text
- e or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.8 Treatment of BRCA -mutated Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Prednisone or Prednisolone Lynparza is indicated in combination with abiraterone and
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6817
- current approval status
- not_reconciled
- duplicate text group
- dup-b538941cc844d165b385
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-30dc198edefa595802d3
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 7143
- end exclusive
- true
- exact text
- Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ].
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 7017
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 46 · positive indication candidate
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 7654
- end exclusive
- true
- exact text
- e progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ]. 1.8 Treatment of BRCA -mutated Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Prednisone or Prednisolone Lynparza is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] .
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 6944
- current approval status
- not_reconciled
- duplicate text group
- dup-be7d728c7ef5ed77c8e1
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-303d32baadbb6f04a910
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- end
- 7307
- end exclusive
- true
- exact text
- is indicated
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 7295
- qualifier mentions
- context exact
- aterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRC
- kind
- age
- polarity
- not_inferred
- span
- end
- 7406
- end exclusive
- true
- exact text
- adult patients
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 7392
- context exact
- 1.8 Treatment of BRCA -mutated Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Predni
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7205
- end exclusive
- true
- exact text
- BRCA -mutated Metastatic Castration-Resistan
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 7161
- context exact
- of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7493
- end exclusive
- true
- exact text
- BRCA-mutated (BRCAm) metastatic castration-r
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 7449
- context exact
- 1.8 Treatment of BRCA -mutated Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Prednisone or Prednis
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7220
- end exclusive
- true
- exact text
- Metastatic Castration-Resistant Prostate Canc
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 7175
- context exact
- h deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7515
- end exclusive
- true
- exact text
- metastatic castration-resistant prostate canc
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 7470
- context exact
- CA -mutated Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Prednisone or Prednisolone Lynparza is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 7402
- end exclusive
- true
- exact text
- in Combination with Abiraterone and Prednisone or Prednisolone Lynparza is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult pati
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 7223
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 7526
- end exclusive
- true
- exact text
- 1.8 Treatment of BRCA -mutated Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Prednisone or Prednisolone Lynparza is indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 7144
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 47 · unclassified context
- application numbers
- NDA208558
- brand names
- Lynparza
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 7654
- end exclusive
- true
- exact text
- abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] .
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 7327
- current approval status
- not_reconciled
- duplicate text group
- dup-b538941cc844d165b385
- extraction review status
- automated_candidate_pending_source_review
- generic names
- OLAPARIB
- id
- ind-span-527af837b6cbf176c742
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- source span
- end
- 7654
- end exclusive
- true
- exact text
- Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] .
- label id
- 0142c57f-6211-4638-8c48-c215686871b8
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 0829a63531a112878e0df65413d64eb3899f7da37ef25d8b85fc40b68bb1531b
- start
- 7527
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%220142c57f-6211-4638-8c48-c215686871b8%22
- spl effective date
- 2025-07-10
- spl set id
- 741ff3e3-dc1a-45a6-84e5-2481b27131aa
- spl version
- 38
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Preserved source evidence · Not medical advice
Triangle